Asia Pacific Chinese Hamster Ovary Cells Cho Market
Taille du marché en milliards USD
TCAC :
% 
 Période de prévision |
2023 –2030 |
 Taille du marché (année de référence) |
USD 77,040.79 Thousand |
 Taille du marché (année de prévision) |
USD 159,123.92 Thousand |
 TCAC |
% |
| Principaux acteurs du marché |
>Marché des cellules ovariennes de hamster chinois (CHO) en Asie-Pacifique, par type (services et produits), système (système de sélection métabolique, système de sélection d'antibiotiques et autres), application (produits biologiques et recherche médicale), utilisateur final (sociétés biopharmaceutiques, sociétés de biotechnologie, organisations de développement clinique et de fabrication, organisations de recherche clinique, instituts universitaires et organisations de recherche, et autres), canal de distribution (appels d'offres directs, ventes au détail et autres) - Tendances et prévisions de l'industrie jusqu'en 2030.
Analyse et perspectives du marché des cellules ovariennes de hamster chinois (CHO) en Asie-Pacifique
Le marché des ovaires de hamster chinois (CHO) de la région Asie-Pacifique est un élément essentiel de l'industrie biopharmaceutique, stimulé par la demande croissante de produits biologiques et de protéines thérapeutiques. Les cellules CHO sont un choix privilégié pour la production biopharmaceutique en raison de leur capacité à exprimer efficacement des protéines complexes avec des modifications post-traductionnelles appropriées.
L'un des principaux moteurs du marché des ovaires de hamster chinois (CHO) en Asie-Pacifique est la demande croissante de produits biopharmaceutiques . Les cellules CHO sont largement utilisées dans la production de produits biopharmaceutiques, notamment d'anticorps monoclonaux, de vaccins et d'autres protéines thérapeutiques. Avec le vieillissement de la population et l'augmentation des besoins en soins de santé, la demande pour ces médicaments avancés augmente dans toute la région Asie-Pacifique. Les cellules CHO offrent une plate-forme fiable et efficace pour la production à grande échelle de produits biopharmaceutiques, ce qui en fait un élément essentiel du processus de biofabrication. En conséquence, le marché des cellules CHO en Asie-Pacifique connaît une croissance constante, car les sociétés pharmaceutiques et les entreprises de biotechnologie cherchent à répondre à la demande de thérapies et de vaccins innovants, ce qui alimente davantage l'adoption de systèmes de production à base de cellules CHO. Cette tendance devrait se poursuivre, faisant du marché des cellules CHO en Asie-Pacifique un acteur important de l'industrie biopharmaceutique mondiale.
Cependant, l’un des défis auxquels est confronté le marché des cellules ovariennes de hamster chinois (CHO) de la région Asie-Pacifique est la complexité réglementaire et la conformité, qui peuvent avoir un impact sur le développement et la production de produits biopharmaceutiques.
Le marché des cellules ovariennes de hamster chinois (CHO) de la région Asie-Pacifique devrait connaître une croissance du marché au cours de la période de prévision de 2023 à 2030. Data Bridge Market Research analyse que le marché croît avec un TCAC de 9,9 % au cours de la période de prévision de 2023 à 2030 et devrait atteindre 159 123,92 milliers USD d'ici 2030 contre 77 040,79 milliers USD en 2022.
Asia-Pacific Chinese Hamster Ovary (CHO) cells market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario, contact us for an analyst brief. Our team will help you create a revenue-impact solution to achieve your desired goal. The scalability and business expansion of the retail units in the developing countries of various regions and partnership with suppliers for the safe distribution of machine and drug products are the major drivers that propelled the demand of the market in the forecast period.
|
Report Metric |
Details |
|
Forecast Period |
2023 to 2030 |
|
Base Year |
2022 |
|
Historic Years |
2021 (Customizable to 2015-2020) |
|
Quantitative Units |
Revenue in USD Thousand |
|
Segments Covered |
Type (Services and Product), System (Metabolic Selection System, Antibiotic Selection System, and Others), Application (Biologics and Medical Research), End-user (Biopharmaceutical Companies, Biotechnology Companies, Clinical Development and Manufacturing Organizations, Clinical Research Organizations, Academic Institutes and Research Organizations, and Others), Distribution Channel (Direct Tenders, Retail Sales and Others) |
|
Countries Covered |
China, Japan, India, Australia, South Korea, New Zealand, Singapore, Thailand, Philippines, Malaysia, Indonesia, Vietnam, Taiwan, and Rest of Asia-Pacific |
|
Market Players Covered |
Thermo Fisher Scientific Inc., AcceGen, RayBiotech Life, Inc., CLS Cell Lines Service GmbH, BPS Bioscience, Inc., GenTarget Inc., Merck KGaA, Abeomics, Applied Biological Materials Inc. (abm), ATCC, Sartorius AG, Lonza, Horizon Discovery Ltd., Cytiva, Curia Global, Inc. among others. |
Market Definition
Chinese Hamster Ovary (CHO) cells are a type of mammalian cell line commonly used in biotechnology and biomedical research, particularly in the field of cell culture and bioprocessing. These cells have become essential tools in biotechnology and biomedical research. CHO cells are known for their adherence to culture surfaces, robust growth characteristics, and ability to express recombinant proteins. Their popularity stems from their similarity to human cells, making them suitable for studying biological processes and producing biopharmaceuticals.
Asia-Pacific Chinese Hamster Ovary (CHO) Cells Market Dynamics
Drivers
- Rising use of CHO cells in the genetic study
The rising use of CHO cells in genetic studies is a significant driver for the Asia-Pacific Chinese Hamster Ovary (CHO) market. CHO cells have gained prominence in genetic research due to their adaptability and versatility in genetic manipulation and expression systems. Researchers and biotechnologists across Asia-Pacific are increasingly relying on CHO cells to investigate various aspects of genetics, including gene expression, genome editing, and functional genomics.
CHO cells provide a stable and well-characterized platform for genetic studies, making them an essential resource for understanding gene function, protein expression, and the development of new therapeutic agents. This heightened interest in genetic research using CHO cells not only fuels the demand for CHO cells but also drives innovations in biotechnology and genetic engineering techniques. Consequently, the Asia-Pacific CHO cell market is experiencing growth as it caters to the expanding needs of the scientific community engaged in genetic research and biotechnology, further solidifying its position in the life sciences sector.
- Growing demand for biopharmaceuticals
The growing demand for biopharmaceuticals is a key driver for the Asia-Pacific Chinese Hamster Ovary (CHO) market. CHO cells play a vital role in the production of biopharmaceuticals, such as monoclonal antibodies, vaccines, and therapeutic proteins. With an aging population and increasing healthcare needs in Asia-Pacific, there is a rising demand for these advanced medicines. CHO cells offer a reliable and efficient platform for large-scale biopharmaceutical production, making them indispensable for the biomanufacturing process. As pharmaceutical companies and biotechnology firms seek to meet the demand for innovative therapies and vaccines, the Asia-Pacific CHO cell market is experiencing steady growth, reinforcing its crucial role in the biopharmaceutical industry.
Opportunity
-
Continuous development of cell culture technologies
The continuous development of cell culture technologies is a critical aspect of biopharmaceutical manufacturing and biotechnology research. These advancements play a pivotal role in improving the production of biological drugs, vaccines, and other biotechnological products. The benefits of ongoing developments in cell culture technologies are
Enhanced Cell Line Development: One of the primary areas of focus in cell culture technology is the development of high-productivity cell lines. Scientists are continually refining methods for selecting, engineering, and optimizing mammalian cell lines, including CHO cells. This involves genetic modifications to increase cell growth rates, protein expression levels, and product quality attributes. These advancements result in more efficient and cost-effective biopharmaceutical production.
Improved Culture Media: Cell culture media are essential for providing cells with the necessary nutrients, growth factors, and environmental conditions for optimal growth and protein expression. Ongoing research aims to develop advanced culture media formulations that enhance cell viability, productivity, and product quality while minimizing production costs. This includes the optimization of chemically defined media to reduce reliance on animal-derived components, improving medium recycling strategies, and tailoring media for specific cell lines and biological products.
Restraints/Challenges
- Time-consuming and inconsistency in the CHO cell line development process
The Asia-Pacific Chinese Hamster Ovary (CHO) market faces the challenge of a time-consuming and often inconsistent CHO cell line development process. Developing stable and high-yielding CHO cell lines for biopharmaceutical production can be a lengthy and resource-intensive endeavor. Variability in cell line performance and characteristics can lead to unpredictability in production, which affects the overall efficiency and cost-effectiveness of biopharmaceutical manufacturing.
The need to optimize and characterize cell lines, select appropriate clones, and achieve consistent productivity levels can extend development timelines and increase operational costs. This challenge not only affects time-to-market for new biopharmaceuticals but also adds complexity to regulatory compliance and quality assurance efforts. Consequently, addressing the time-consuming and inconsistent nature of the CHO cell line development process is essential to enhance the competitiveness of the Asia-Pacific CHO cell market in the biopharmaceutical industry.
- High cost of CHO cell-based production
The high cost of CHO cell-based production is a significant restraint in the biopharmaceutical manufacturing industry. Several factors contribute to the elevated costs are mentioned below.
The upstream process in CHO cell-based production is complex. It involves the cultivation of mammalian cells in bioreactors, which necessitates strict control over various parameters such as temperature, pH, oxygen levels, and nutrient supply. Maintaining these optimal conditions for cell growth and protein expression requires specialized equipment and skilled personnel, adding to the overall cost.
Cell line development is another resource-intensive step. Creating highly productive CHO cell lines involves selecting suitable cells and genetically modifying them to express the desired therapeutic protein efficiently. This process involves substantial research efforts, extensive genetic engineering, and rigorous screening, all of which demand time and resources.
In addition, the cost of culture media and nutrients for CHO cells is a significant contributor. These cells require specific growth media containing essential nutrients, growth factors, and supplements. The expense of procuring these high-quality culture media can accumulate significantly over large-scale production runs. Researchers continually work on optimizing media formulations to reduce costs while maintaining cell performance.
Recent Developments
- In July 2023, Lonza has introduced the TheraPRO CHO Media System, an innovative cell culture solution designed to streamline procedures and enhance both productivity and protein quality, particularly in conjunction with GS-CHO cell lines. This product launch is aimed at assisting pharmaceutical and biotechnology enterprises in their efforts to produce therapeutic proteins of higher quality and expedite their time-to-market
- In October 2022, after the favorable reception of the Gibco Freedom CHO-S Cell Line Development Kit, ProBioGen and Thermo Fisher Scientific collaborated once more to create an enhanced solution: the Gibco Freedom ExpiCHO-S Cell Line Development Kit. This advanced platform enables users to establish cell lines suitable for clinical development, even without possessing their own initial cells, vectors, or prior expertise in the domain. Leveraging their profound knowledge in cell line and process development, ProBioGen has significantly enhanced the performance of the Freedom ExpiCHO-S Kit
Asia-Pacific Chinese Hamster Ovary (CHO) Cells Market Scope
Asia-Pacific Chinese Hamster Ovary (CHO) cells market is categorized into five notable segments based on type, system, application, end-user, and distribution channel.The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Type
- Services
- Products
On the basis of type, the Asia-Pacific Chinese Hamster Ovary (CHO) market is segmented into services and product.
System
- Metabolic Selection System
- Antibiotic Selection System
- Others
On the basis of systems, the Asia-Pacific Chinese Hamster Ovary (CHO) market is segmented into metabolic selection system, antibiotic selection system, and others.
Application
- Biologics
- Medical Research
On the basis of application, the Asia-Pacific Chinese Hamster Ovary (CHO) market is segmented into biologics and medical research.
End-User
- Biopharmaceutical Companies
- Biotechnology Companies
- Clinical Development and Manufacturing Organizations
- Clinical Research Organizations
- Academic Institutes and Research Organizations
- Others
On the basis of end-user, the Asia-Pacific Chinese Hamster Ovary (CHO) market is segmented into biopharmaceutical companies, biotechnology companies, clinical development and manufacturing organizations, clinical research organizations, academic institutes and research organizations, and others.
Distribution Channel
- Direct Tenders
- Retail Sales
- Others
Sur la base du canal de distribution, le marché des ovaires de hamster chinois (CHO) de la région Asie-Pacifique est segmenté en appels d'offres directs, ventes au détail et autres.
Analyse/perspectives régionales du marché des cellules ovariennes de hamster chinois (CHO) en Asie-Pacifique
Le marché des cellules ovariennes de hamster chinois (CHO) de la région Asie-Pacifique est classé en cinq segments notables en fonction du type, du système, de l’application, de l’utilisateur final et du canal de distribution.
Les pays couverts par ce rapport de marché sont la Chine, le Japon, l'Inde, l'Australie, la Corée du Sud, la Nouvelle-Zélande, Singapour, la Thaïlande, les Philippines, la Malaisie, l'Indonésie, le Vietnam, Taïwan et le reste de l'Asie-Pacifique.
La Chine domine la région Asie-Pacifique et devrait croître avec le TCAC le plus élevé au cours de la période de prévision en raison des solides capacités de recherche et développement du pays dans les industries biopharmaceutiques.
La section par pays du rapport fournit également des facteurs individuels ayant un impact sur le marché et des changements dans la réglementation du marché national qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que les nouvelles ventes, les ventes de remplacement, la démographie du pays, les actes réglementaires et les tarifs douaniers d'import-export sont quelques-uns des principaux indicateurs utilisés pour prévoir le scénario du marché pour les différents pays. En outre, la présence et la disponibilité des marques d'Asie-Pacifique et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, ainsi que l'impact des canaux de vente sont pris en compte lors de l'analyse prévisionnelle des données nationales.
Analyse du paysage concurrentiel et des parts de marché des cellules ovariennes de hamster chinois (CHO) en Asie-Pacifique
Le paysage concurrentiel du marché des cellules ovariennes de hamster chinois (CHO) en Asie-Pacifique fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements en R&D, les nouvelles initiatives du marché, les sites et installations de production, les forces et les faiblesses de l'entreprise, le lancement du produit, les approbations de produits, la largeur et la portée du produit, la domination des applications et la courbe de survie du type de produit. Les points de données ci-dessus fournis ne concernent que l'orientation de l'entreprise sur le marché des cellules ovariennes de hamster chinois (CHO) en Asie-Pacifique.
Français Certains des principaux acteurs opérant sur le marché des cellules d'ovaire de hamster chinois (CHO) en Asie-Pacifique sont Thermo Fisher Scientific Inc., AcceGen, RayBiotech Life, Inc., CLS Cell Lines Service GmbH, BPS Bioscience, Inc., GenTarget Inc., Merck KGaA, Abeomics, Applied Biological Materials Inc. (abm), ATCC, Sartorius AG, Lonza, Horizon Discovery Ltd., Cytiva, Curia Global, Inc. entre autres. entre autres.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE ASIA-PACIFIC CHINESE HAMSTER OVARY CELLS (CHO) MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 BY TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
5 ASIA-PACIFIC CHINESE HAMSTER OVARY CELLS (CHO) MARKET, REGULATIONS
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING USE OF CHO CELLS IN THE GENETIC STUDY
6.1.2 GROWING DEMAND FOR BIOPHARMACEUTICALS
6.1.3 RISING INVESTMENTS IN BIOTECHNOLOGY R&D
6.1.4 RISING DEMAND FOR MONOCLONAL ANTIBODIES
6.2 RESTRAINTS
6.2.1 HIGH-COST OF CHO CELL-BASED PRODUCTION
6.2.2 STRICT REGULATORY REQUIREMENTS FOR CHO CELL-BASED PRODUCTION
6.3 OPPORTUNITIES
6.3.1 CONTINUOUS DEVELOPMENT OF CELL CULTURE TECHNOLOGIES
6.3.2 RISING NUMBER OF APPLICATIONS OF CHO CELLS
6.4 CHALLENGES
6.4.1 TIME-CONSUMING AND INCONSISTENCY IN THE CHO CELL LINE DEVELOPMENT PROCESS
6.4.2 CONTAMINATION RISK OF CHO CELL CULTURES
7 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE
7.1 OVERVIEW
7.2 SERVICES
7.3 PRODUCT
7.3.1 CHO-DXB11
7.3.2 CHO-K1
7.3.2.1 CHO-K1 ATCC
7.3.2.2 CHO-K1 ECACC
7.3.2.3 OTHERS
7.3.3 CHO-DG44
7.3.4 CHO-S
7.3.5 OTHERS
8 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY SYSTEM
8.1 OVERVIEW
8.2 METABOLIC SELECTION SYSTEM
8.3 ANTIBIOTIC SELECTION SYSTEM
8.4 OTHERS
9 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION
9.1 OVERVIEW
9.2 BIOLOGICS
9.2.1 MONOCLONAL ANTIBODIES
9.2.2 ENZYMES
9.2.3 CYTOKINES
9.2.4 CLOTTING FACTORS
9.2.5 HORMONES
9.2.6 FC-FUSION PROTIEN
9.2.7 OTHERS
9.3 MEDICAL RESEARCH
10 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY END USER
10.1 OVERVIEW
10.2 BIOPHARMACEUTICAL COMPANIES
10.2.1 MEDIUM
10.2.2 SMALL
10.3 BIOTECHNOLOGY COMPANIES
10.3.1 MEDIUM
10.3.2 SMALL
10.4 CLINICAL DEVELOPMENT AND MANUFACTURING ORGANIZATIONS
10.4.1 MEDIUM
10.4.2 SMALL
10.5 CLINICAL RESEARCH ORGANIZATIONS
10.5.1 MEDIUM
10.5.2 SMALL
10.6 ACADEMIC INSTITUTES AND RESEARCH ORGANIZATIONS
10.7 OTHERS
11 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY DISTRIBUTION CHANNEL
11.1 OVERVIEW
11.2 DIRECT TENDERS
11.3 RETAIL SALES
11.4 OTHERS
12 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY COUNTRY
12.1 ASIA-PACIFIC
12.1.1 CHINA
12.1.2 JAPAN
12.1.3 INDIA
12.1.4 AUSTRALIA
12.1.5 SOUTH KOREA
12.1.6 NEW ZEALAND
12.1.7 SINGAPORE
12.1.8 THAILAND
12.1.9 PHILIPPINES
12.1.10 MALAYSIA
12.1.11 INDONESIA
12.1.12 VIETNAM
12.1.13 TAIWAN
12.1.14 REST OF ASIA-PACIFIC
13 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET, COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
14 SWOT ANALYSIS
15 COMPANY PROFILE
15.1 SARTORIUS AG
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 PRODUCT PORTFOLIO
15.1.4 RECENT DEVELOPMENT
15.2 LONZA
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 PRODUCT PORTFOLIO
15.2.4 RECENT DEVELOPMENT
15.3 MERCK KGAA
15.3.1 COMPANY SNAPSHOT
15.3.2 REVENUE ANALYSIS
15.3.3 PRODUCT PORTFOLIO
15.3.4 RECENT DEVELOPMENT
15.4 CYTIVA
15.4.1 COMPANY SNAPSHOT
15.4.2 PRODUCT PORTFOLIO
15.4.3 RECENT DEVELOPMENT
15.5 THERMO FISHER SCIENTIFIC INC.
15.5.1 COMPANY SNAPSHOT
15.5.2 REVENUE ANALYSIS
15.5.3 PRODUCT PORTFOLIO
15.5.4 RECENT DEVELOPMENT
15.6 ABEOMICS
15.6.1 COMPANY SNAPSHOT
15.6.2 PRODUCT PORTFOLIO
15.6.3 RECENT DEVELOPMENT
15.7 ACCEGEN
15.7.1 COMPANY SNAPSHOT
15.7.2 PRODUCT PORTFOLIO
15.7.3 RECENT DEVELOPMENT
15.8 APPLIED BIOLOGICAL MATERIALS INC. (ABM)
15.8.1 COMPANY SNAPSHOT
15.8.2 PRODUCT PORTFOLIO
15.8.3 RECENT DEVELOPMENT
15.9 ATCC
15.9.1 COMPANY SNAPSHOT
15.9.2 PRODUCT PORTFOLIO
15.9.3 RECENT DEVELOPMENT
15.1 BPS BIOSCIENCE, INC.
15.10.1 COMPANY SNAPSHOT
15.10.2 PRODUCT PORTFOLIO
15.10.3 RECENT DEVELOPMENT
15.11 CLS CELL LINES SERVICE GMBH
15.11.1 COMPANY SNAPSHOT
15.11.2 PRODUCT PORTFOLIO
15.11.3 RECENT DEVELOPMENT
15.12 CURIA GLOBAL, INC.
15.12.1 COMPANY SNAPSHOT
15.12.2 PRODUCT PORTFOLIO
15.12.3 RECENT DEVELOPMENT
15.13 GENTARGET INC.
15.13.1 COMPANY SNAPSHOT
15.13.2 PRODUCT PORTFOLIO
15.13.3 RECENT DEVELOPMENT
15.14 HORIZON DISCOVERY LTD.
15.14.1 COMPANY SNAPSHOT
15.14.2 PRODUCT PORTFOLIO
15.14.3 RECENT DEVELOPMENT
15.15 PROMEGA CORPORATION
15.15.1 COMPANY SNAPSHOT
15.15.2 PRODUCT PORTFOLIO
15.15.3 RECENT DEVELOPMENT
15.16 RAYBIOTECH LIFE, INC.
15.16.1 COMPANY SNAPSHOT
15.16.2 PRODUCT PORTFOLIO
15.16.3 RECENT DEVELOPMENT
16 QUESTIONNAIRE
17 RELATED REPORTS
Liste des tableaux
TABLE 1 ICH GUIDELINES FOR CHO CELL-BASED PRODUCTS
TABLE 2 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2022-2030 (USD THOUSAND)
TABLE 3 ASIA-PACIFIC PRODUCT IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 4 ASIA-PACIFIC CHO-K1 IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 5 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY SYSTEM, 2021-2030 (USD THOUSAND)
TABLE 6 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 7 ASIA-PACIFIC BIOLOGICS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 8 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 9 ASIA-PACIFIC BIOPHARMACEUTICAL COMPANIES IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 10 ASIA-PACIFIC BIOTECHNOLOGY COMPANIES IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 11 ASIA-PACIFIC CLINICAL DEVELOPMENT AND MANUFACTURING ORGANIZATIONS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 12 ASIA-PACIFIC CLINICAL RESEARCH ORGANIZATIONS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 13 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 14 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)
TABLE 15 CHINA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 16 CHINA PRODUCT IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 17 CHINA PRODUCT IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 ASP
TABLE 18 CHINA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 19 CHINA CHO-K1 IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 20 CHINA CHO-K1 IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 ASP
TABLE 21 CHINA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 22 CHINA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY SYSTEM, 2021-2030 (USD THOUSAND)
TABLE 23 CHINA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 24 CHINA BIOLOGICS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 25 CHINA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 26 CHINA BIOPHARMACEUTICAL COMPANIES IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 27 CHINA BIOTECHNOLOGY COMPANIES IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 28 CHINA CLINICAL DEVELOPMENT AND MANUFACTURING ORGANIZATIONS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 29 CHINA CLINICAL RESEARCH ORGANIZATIONS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 30 CHINA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 31 JAPAN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 32 JAPAN PRODUCT IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 33 JAPAN PRODUCT IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 ASP
TABLE 34 JAPAN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 35 JAPAN CHO-K1 IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 36 JAPAN CHO-K1 IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 ASP
TABLE 37 JAPAN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 38 JAPAN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY SYSTEM, 2021-2030 (USD THOUSAND)
TABLE 39 JAPAN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 40 JAPAN BIOLOGICS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 41 JAPAN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 42 JAPAN BIOPHARMACEUTICAL COMPANIES IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 43 JAPAN BIOTECHNOLOGY COMPANIES IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 44 JAPAN CLINICAL DEVELOPMENT AND MANUFACTURING ORGANIZATIONS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 45 JAPAN CLINICAL RESEARCH ORGANIZATIONS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 46 JAPAN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 47 INDIA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 48 INDIA PRODUCT IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 49 INDIA PRODUCT IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 ASP
TABLE 50 INDIA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 51 INDIA CHO-K1 IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 52 INDIA CHO-K1 IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 ASP
TABLE 53 INDIA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 54 INDIA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY SYSTEM, 2021-2030 (USD THOUSAND)
TABLE 55 INDIA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 56 INDIA BIOLOGICS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 57 INDIA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 58 INDIA BIOPHARMACEUTICAL COMPANIES IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 59 INDIA BIOTECHNOLOGY COMPANIES IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 60 INDIA CLINICAL DEVELOPMENT AND MANUFACTURING ORGANIZATIONS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 61 INDIA CLINICAL RESEARCH ORGANIZATIONS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 62 INDIA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 63 AUSTRALIA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 64 AUSTRALIA PRODUCT IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 65 AUSTRALIA PRODUCT IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 ASP
TABLE 66 AUSTRALIA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 67 AUSTRALIA CHO-K1 IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 68 AUSTRALIA CHO-K1 IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 ASP
TABLE 69 AUSTRALIA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 70 AUSTRALIA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY SYSTEM, 2021-2030 (USD THOUSAND)
TABLE 71 AUSTRALIA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 72 AUSTRALIA BIOLOGICS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 73 AUSTRALIA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 74 AUSTRALIA BIOPHARMACEUTICAL COMPANIES IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 75 AUSTRALIA BIOTECHNOLOGY COMPANIES IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 76 AUSTRALIA CLINICAL DEVELOPMENT AND MANUFACTURING ORGANIZATIONS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 77 AUSTRALIA CLINICAL RESEARCH ORGANIZATIONS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 78 AUSTRALIA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 79 SOUTH KOREA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 80 SOUTH KOREA PRODUCT IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 81 SOUTH KOREA PRODUCT IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 ASP
TABLE 82 SOUTH KOREA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 83 SOUTH KOREA CHO-K1 IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 84 SOUTH KOREA CHO-K1 IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 ASP
TABLE 85 SOUTH KOREA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 86 SOUTH KOREA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY SYSTEM, 2021-2030 (USD THOUSAND)
TABLE 87 SOUTH KOREA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 88 SOUTH KOREA BIOLOGICS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 89 SOUTH KOREA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 90 SOUTH KOREA BIOPHARMACEUTICAL COMPANIES IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 91 SOUTH KOREA BIOTECHNOLOGY COMPANIES IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 92 SOUTH KOREA CLINICAL DEVELOPMENT AND MANUFACTURING ORGANIZATIONS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 93 SOUTH KOREA CLINICAL RESEARCH ORGANIZATIONS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 94 SOUTH KOREA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 95 NEW ZEALAND CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 96 NEW ZEALAND PRODUCT IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 97 NEW ZEALAND PRODUCT IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 ASP
TABLE 98 NEW ZEALAND CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 99 NEW ZEALAND CHO-K1 IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 100 NEW ZEALAND CHO-K1 IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 ASP
TABLE 101 NEW ZEALAND CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 102 NEW ZEALAND CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY SYSTEM, 2021-2030 (USD THOUSAND)
TABLE 103 NEW ZEALAND CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 104 NEW ZEALAND BIOLOGICS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 105 NEW ZEALAND CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 106 NEW ZEALAND BIOPHARMACEUTICAL COMPANIES IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 107 NEW ZEALAND BIOTECHNOLOGY COMPANIES IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 108 NEW ZEALAND CLINICAL DEVELOPMENT AND MANUFACTURING ORGANIZATIONS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 109 NEW ZEALAND CLINICAL RESEARCH ORGANIZATIONS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 110 NEW ZEALAND CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 111 SINGAPORE CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 112 SINGAPORE PRODUCT IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 113 SINGAPORE PRODUCT IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 ASP
TABLE 114 SINGAPORE CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 115 SINGAPORE CHO-K1 IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 116 SINGAPORE CHO-K1 IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 ASP
TABLE 117 SINGAPORE CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 118 SINGAPORE CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY SYSTEM, 2021-2030 (USD THOUSAND)
TABLE 119 SINGAPORE CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 120 SINGAPORE BIOLOGICS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 121 SINGAPORE CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 122 SINGAPORE BIOPHARMACEUTICAL COMPANIES IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 123 SINGAPORE BIOTECHNOLOGY COMPANIES IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 124 SINGAPORE CLINICAL DEVELOPMENT AND MANUFACTURING ORGANIZATIONS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 125 SINGAPORE CLINICAL RESEARCH ORGANIZATIONS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 126 SINGAPORE CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 127 THAILAND CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 128 THAILAND PRODUCT IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 129 THAILAND PRODUCT IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 ASP
TABLE 130 THAILAND CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 131 THAILAND CHO-K1 IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 132 THAILAND CHO-K1 IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 ASP
TABLE 133 THAILAND CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 134 THAILAND CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY SYSTEM, 2021-2030 (USD THOUSAND)
TABLE 135 THAILAND CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 136 THAILAND BIOLOGICS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 137 THAILAND CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 138 THAILAND BIOPHARMACEUTICAL COMPANIES IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 139 THAILAND BIOTECHNOLOGY COMPANIES IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 140 THAILAND CLINICAL DEVELOPMENT AND MANUFACTURING ORGANIZATIONS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 141 THAILAND CLINICAL RESEARCH ORGANIZATIONS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 142 THAILAND CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 143 PHILIPPINES CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 144 PHILIPPINES PRODUCT IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 145 PHILIPPINES PRODUCT IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 ASP
TABLE 146 PHILIPPINES CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 147 PHILIPPINES CHO-K1 IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 148 PHILIPPINES CHO-K1 IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 ASP
TABLE 149 PHILIPPINES CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 150 PHILIPPINES CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY SYSTEM, 2021-2030 (USD THOUSAND)
TABLE 151 PHILIPPINES CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 152 PHILIPPINES BIOLOGICS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 153 PHILIPPINES CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 154 PHILIPPINES BIOPHARMACEUTICAL COMPANIES IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 155 PHILIPPINES BIOTECHNOLOGY COMPANIES IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 156 PHILIPPINES CLINICAL DEVELOPMENT AND MANUFACTURING ORGANIZATIONS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 157 PHILIPPINES CLINICAL RESEARCH ORGANIZATIONS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 158 PHILIPPINES CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 159 MALAYSIA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 160 MALAYSIA PRODUCT IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 161 MALAYSIA PRODUCT IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 ASP
TABLE 162 MALAYSIA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 163 MALAYSIA CHO-K1 IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 164 MALAYSIA CHO-K1 IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 ASP
TABLE 165 MALAYSIA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 166 MALAYSIA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY SYSTEM, 2021-2030 (USD THOUSAND)
TABLE 167 MALAYSIA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 168 MALAYSIA BIOLOGICS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 169 MALAYSIA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 170 MALAYSIA BIOPHARMACEUTICAL COMPANIES IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 171 MALAYSIA BIOTECHNOLOGY COMPANIES IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 172 MALAYSIA CLINICAL DEVELOPMENT AND MANUFACTURING ORGANIZATIONS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 173 MALAYSIA CLINICAL RESEARCH ORGANIZATIONS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 174 MALAYSIA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 175 INDONESIA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 176 INDONESIA PRODUCT IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 177 INDONESIA PRODUCT IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 ASP
TABLE 178 INDONESIA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 179 INDONESIA CHO-K1 IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 180 INDONESIA CHO-K1 IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 ASP
TABLE 181 INDONESIA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 182 INDONESIA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY SYSTEM, 2021-2030 (USD THOUSAND)
TABLE 183 INDONESIA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 184 INDONESIA BIOLOGICS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 185 INDONESIA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 186 INDONESIA BIOPHARMACEUTICAL COMPANIES IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 187 INDONESIA BIOTECHNOLOGY COMPANIES IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 188 INDONESIA CLINICAL DEVELOPMENT AND MANUFACTURING ORGANIZATIONS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 189 INDONESIA CLINICAL RESEARCH ORGANIZATIONS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 190 INDONESIA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 191 VIETNAM CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 192 VIETNAM PRODUCT IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 193 VIETNAM PRODUCT IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 ASP
TABLE 194 VIETNAM CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 195 VIETNAM CHO-K1 IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 196 VIETNAM CHO-K1 IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 ASP
TABLE 197 VIETNAM CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 198 VIETNAM CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY SYSTEM, 2021-2030 (USD THOUSAND)
TABLE 199 VIETNAM CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 200 VIETNAM BIOLOGICS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 201 VIETNAM CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 202 VIETNAM BIOPHARMACEUTICAL COMPANIES IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 203 VIETNAM BIOTECHNOLOGY COMPANIES IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 204 VIETNAM CLINICAL DEVELOPMENT AND MANUFACTURING ORGANIZATIONS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 205 VIETNAM CLINICAL RESEARCH ORGANIZATIONS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 206 VIETNAM CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 207 TAIWAN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 208 TAIWAN PRODUCT IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 209 TAIWAN PRODUCT IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 ASP
TABLE 210 TAIWAN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 211 TAIWAN CHO-K1 IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 212 TAIWAN CHO-K1 IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 ASP
TABLE 213 TAIWAN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 214 TAIWAN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY SYSTEM, 2021-2030 (USD THOUSAND)
TABLE 215 TAIWAN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 216 TAIWAN BIOLOGICS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 217 TAIWAN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 218 TAIWAN BIOPHARMACEUTICAL COMPANIES IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 219 TAIWAN BIOTECHNOLOGY COMPANIES IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 220 TAIWAN CLINICAL DEVELOPMENT AND MANUFACTURING ORGANIZATIONS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 221 TAIWAN CLINICAL RESEARCH ORGANIZATIONS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 222 TAIWAN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 223 REST OF ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
Liste des figures
FIGURE 1 ASIA-PACIFIC CHINESE HAMSTER OVARY CELLS (CHO) MARKET: SEGMENTATION
FIGURE 2 ASIA-PACIFIC CHINESE HAMSTER OVARY CELLS (CHO) MARKET: DATA TRIANGULATION
FIGURE 3 ASIA-PACIFIC CHINESE HAMSTER OVARY CELLS (CHO) MARKET: DROC ANALYSIS
FIGURE 4 ASIA-PACIFIC CHINESE HAMSTER OVARY CELLS (CHO) MARKET: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA-PACIFIC CHINESE HAMSTER OVARY CELLS (CHO) MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA-PACIFIC CHINESE HAMSTER OVARY CELLS (CHO) MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA-PACIFIC CHINESE HAMSTER OVARY CELLS (CHO) MARKET: DBMR MARKET POSITION GRID
FIGURE 8 ASIA-PACIFIC CHINESE HAMSTER OVARY CELLS (CHO) MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 ASIA-PACIFIC CHINESE HAMSTER OVARY CELLS (CHO) MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA-PACIFIC CHINESE HAMSTER OVARY CELLS (CHO) MARKET: SEGMENTATION
FIGURE 11 GROWING DEMAND FOR BIOPHARMACEUTICALS IS EXPECTED TO DRIVE THE ASIA-PACIFIC CHINESE HAMSTER OVARY CELLS (CHO) MARKET GROWTH IN THE FORECAST PERIOD OF 2023 TO 2030
FIGURE 12 SERVICES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC CHINESE HAMSTER OVARY CELLS (CHO) MARKET IN THE FORECAST PERIOD OF 2023 & 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA-PACIFIC CHINESE HAMSTER OVARY CELLS (CHO) MARKET
FIGURE 14 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET: BY TYPE, 2022
FIGURE 15 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET: BY TYPE, 2023-2030 (USD THOUSAND)
FIGURE 16 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET: BY TYPE, CAGR (2023-2030)
FIGURE 17 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 18 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET: BY SYSTEM, 2022
FIGURE 19 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET: BY SYSTEM, 2023-2030 (USD THOUSAND)
FIGURE 20 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET: BY SYSTEM, CAGR (2023-2030)
FIGURE 21 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET: BY SYSTEM, LIFELINE CURVE
FIGURE 22 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET: BY APPLICATION, 2022
FIGURE 23 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET: BY APPLICATION, 2023-2030 (USD THOUSAND)
FIGURE 24 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET: BY APPLICATION, CAGR (2023-2030)
FIGURE 25 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 26 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET: BY END USER, 2022
FIGURE 27 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET: BY END USER, 2023-2030 (USD THOUSAND)
FIGURE 28 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET: BY END USER, CAGR (2023-2030)
FIGURE 29 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET: BY END USER, LIFELINE CURVE
FIGURE 30 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET: BY END USER, 2022
FIGURE 31 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET: BY END USER, 2023-2030 (USD THOUSAND)
FIGURE 32 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET: BY END USER, CAGR (2023-2030)
FIGURE 33 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET: BY END USER, LIFELINE CURVE
FIGURE 34 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET SNAPSHOT
FIGURE 35 ASIA-PACIFIC CHINESE HAMSTER OVARY (CHO) CELLS MARKET: COMPANY SHARE 2022 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
